Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kevin Serrano

Physician Assistant Naperville, IL Physician Assistant

NPI 1255962445 CMS profile 10626397

1952 Mc Dowell Rd Ste 305, Naperville, IL 60563

Open in the dashboard

General payments

$14,905

724 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Serrano of Naperville, IL is reported in the CMS Open Payments database as having received $14,905 across 724 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,162 203
2024 General $4,299 183
2023 General $2,225 115
2022 General $2,356 124
2021 General $1,864 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Serrano
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kevin Serrano were reported at $4,162. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kevin Serrano Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,864 $132 $37–$438 $132
2022 $2,356 $155 $48–$522 $149
2023 $2,225 $167 $52–$557 $160
2024 $4,299 $178 $55–$600 $164
2025 $4,162 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Corium, Inc. $1,512 75 payments
  2. AbbVie, Inc. $1,506 77 payments
  3. Vanda Pharmaceuticals Inc. $1,253 49 payments
  4. ITI, Inc. $967 50 payments
  5. Janssen Pharmaceuticals, Inc $955 47 payments
  6. Otsuka America Pharmaceutical, Inc. $927 46 payments
  7. Neurocrine Biosciences, Inc. $744 31 payments
  8. Alkermes, Inc. $691 38 payments
  9. Supernus Pharmaceuticals, Inc. $687 18 payments
  10. Tris Pharma Inc $686 42 payments
  11. Other $4,977 251 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,615 720 payments
  2. Education $175 3 payments
  3. Consulting Fee $115 1 payment
Products named General payments · program years 2021–2025
  1. Azstarys $1,512 75 payments
  2. VRAYLAR $1,127 54 payments
  3. FANAPT $976 38 payments
  4. SPRAVATO $886 41 payments
  5. REXULTI Psychiatry $797 39 payments
  6. CAPLYTA $650 36 payments
  7. LYBALVI $643 35 payments
  8. LOREEV XR $615 31 payments
  9. REXULTI Psychiatry $614 37 payments
  10. ARISTADA $608 34 payments
  11. Other $10,558 547 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

359

Median for Physician Assistant: 241

Drug cost

$22,639

Median for Physician Assistant: $4,110

Branded share of claims

17%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 11 $18,535
Quetiapine Fumarate Generic 32 $619
Divalproex Sodium Generic 22 $446
Escitalopram Oxalate Generic 29 $336
Venlafaxine Hcl Er Venlafaxine Hcl Brand 33 $328
Duloxetine Hcl Generic 14 $318
Fluoxetine Hcl Generic 17 $292
Topiramate Generic 11 $256
Bupropion Xl Bupropion Hcl Brand 17 $254
Risperidone Generic 18 $245

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$9,562

Medicare's payments for the services billed

Medicare patients

25

Average age 61

Services billed

146

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 56%
Arthritis 52%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Azstarys
  • Corium, Inc. $545
$545 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $487
$487 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $280
  • Lundbeck LLC $149
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $46
$475 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $209
  • Janssen Scientific Affairs, LLC $115
$324 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $317
$317 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

724 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record